Literature DB >> 16585159

Mitosis-independent survivin gene expression in vivo and regulation by p53.

Fang Xia1, Dario C Altieri.   

Abstract

Survivin is an essential mitotic gene, and this has been speculated to reflect its primary function in development and cancer. Here, we generated a knock-in transgenic mouse (SVVp-GFP) in which a green fluorescent protein (GFP) reporter gene was placed under the control of the survivin promoter that regulates transcription at mitosis. The expression of endogenous survivin was widespread in mouse tissues during development and shortly after birth. In contrast, GFP reactivity was undetectable in transgenic mouse embryos, and was largely limited postnatally to mitotic cells in the testes. Double transgenic mice generated in the tumor-prone Min/+ background exhibited intestinal adenomas that strongly expressed endogenous survivin, but only isolated GFP-positive cells. Conversely, dysplastic adenomas (16%) stained intensely for GFP, and revealed focal reactivity for mutant, but not wild-type, p53. The expression of GFP was increased by approximately 10-fold in p53(-/-) as opposed to p53(+/+) HCT116 colorectal cancer cells, and reintroduction of p53 in p53(-/-) cells abolished GFP expression. Therefore, the mitotic transcription of the survivin gene is highly restricted in vivo, and unexpectedly negatively regulated by p53. Contrary to a commonly held view, the dominant function(s) of survivin in development and tumor ontogeny are largely cell cycle-independent.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16585159     DOI: 10.1158/0008-5472.CAN-05-4537

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  21 in total

1.  Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis.

Authors:  Connie W Lee; Christopher M Raskett; Igor Prudovsky; Dario C Altieri
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

2.  Developmental control of apoptosis by the immunophilin aryl hydrocarbon receptor-interacting protein (AIP) involves mitochondrial import of the survivin protein.

Authors:  Byoung Heon Kang; Fang Xia; Ramona Pop; Takehiko Dohi; Merav Socolovsky; Dario C Altieri
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

Review 3.  Survivin and IAP proteins in cell-death mechanisms.

Authors:  Dario C Altieri
Journal:  Biochem J       Date:  2010-09-01       Impact factor: 3.857

4.  Cellular and molecular phenotypes of proliferating stromal cells from human carcinomas.

Authors:  E P Kopantzev; N A Vayshlya; M R Kopantseva; V I Egorov; M Pikunov; M V Zinovyeva; T V Vinogradova; I B Zborovskaya; E D Sverdlov
Journal:  Br J Cancer       Date:  2010-04-20       Impact factor: 7.640

5.  hTERT and BIRC5 gene promoters for cancer gene therapy: A comparative study.

Authors:  Mikhail V Shepelev; Eugene P Kopantzev; Tatiana V Vinogradova; Eugene D Sverdlov; Igor V Korobko
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

Review 6.  Survivin as a global target of intrinsic tumor suppression networks.

Authors:  Minakshi Guha; Dario C Altieri
Journal:  Cell Cycle       Date:  2009-09-07       Impact factor: 4.534

7.  Survivin repression by p53, Rb and E2F2 in normal human melanocytes.

Authors:  Deepak Raj; Tong Liu; George Samadashwily; Fengzhi Li; Douglas Grossman
Journal:  Carcinogenesis       Date:  2007-10-04       Impact factor: 4.944

Review 8.  New wirings in the survivin networks.

Authors:  D C Altieri
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

9.  A functional Notch-survivin gene signature in basal breast cancer.

Authors:  Connie W Lee; Karl Simin; Qin Liu; Janet Plescia; Minakshi Guha; Ashraf Khan; Chung-Cheng Hsieh; Dario C Altieri
Journal:  Breast Cancer Res       Date:  2008-11-24       Impact factor: 6.466

10.  Caspase 2-mediated tumor suppression involves survivin gene silencing.

Authors:  M Guha; F Xia; C M Raskett; D C Altieri
Journal:  Oncogene       Date:  2009-11-23       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.